Clinical Trial Update: Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection [NA]

View source ↗

Summary

A clinical trial evaluating heparin vs. M-EDTA as catheter lock solutions to prevent infections and blockages in high-risk cancer patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Heparin (unfractionated heparin)
• M-EDTA (M-EDTA)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Cancer | NA | Status: WITHDRAWN